Morgan Stanley Starts Optimer Pharmaceuticals (OPTR) at Underweight

Article Stock Quotes (1) Comments (0)

Optimer Pharmaceuticals (NASDAQ: OPTR) is getting wrecked today after Morgan Stanley initiated coverage on the stock with a dreaded 'Underweight' rating and downside price target of $11 price target, or 14 percent Wednesday's close.

The firm said reimbursement hurdles, sluggish launch trends, and a lack of clear long-term growth drivers limit sales expectations for Dificid.

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals last traded at $11.90, down 7 percent.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
• Wells Fargo Starts Quintiles (Q) at Outperform
• UPDATE: Canaccord Genuity Starts T-Mobile US, (TMUS) at Hold

Create E-mail Alert Related Categories

New Coverage

Related Entities

Morgan Stanley

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?